GLTO trades 102.4% below Wall Street's consensus target of $43.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GLTO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Galecto, Inc. (GLTO) has a Wall Street consensus price target of $43.67, based on estimates from 5 covering analysts. With the stock currently trading at $21.58, this represents a potential upside of +102.4%. The company has a market capitalization of $34M.
Analyst price targets range from a low of $40.00 to a high of $46.00, representing a 14% spread in expectations. The median target of $45.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, GLTO trades at a trailing P/E of -5.8x. Analysts expect EPS to grow +99.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
GALTGalectin Therapeutics Inc. | $329M | $4.99 | $11.00 | +120.4% | Buy | — | 11 |
IMVTImmunovant, Inc. | $8.0B | $38.85 | $45.00 | +15.8% | Buy | — | 23 |
BCABBioAtla, Inc. | $5M | $3.68 | $250.00 | +6693.5% | Buy | — | 9 |
TGTXTG Therapeutics, Inc. | $8.5B | $55.83 | $64.00 | +14.6% | Buy | 41.1x | 13 |
PRTAProthena Corporation plc | $525M | $10.02 | $19.00 | +89.6% | Buy | 214.6x | 28 |
ARQTArcutis Biotherapeutics, Inc. | $3.4B | $27.00 | $34.00 | +25.9% | Buy | 135.6x | 12 |
IDYAIDEAYA Biosciences, Inc. | $3.2B | $36.74 | $58.67 | +59.7% | Buy | — | 25 |
KYMRKymera Therapeutics, Inc. | $8.8B | $108.12 | $123.50 | +14.2% | Buy | — | 26 |
RVMDRevolution Medicines, Inc. | $38.7B | $182.08 | $165.75 | -9.0% | Buy | — | 22 |
FBRXForte Biosciences, Inc. | $3.8B | $21.03 | $65.00 | +209.1% | Buy | — | 6 |
Quick answers to the most common questions about buying GLTO stock.
The consensus Wall Street price target for GLTO is $43.67, representing 102.4% upside from the current price of $21.58. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
GLTO has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $43.67 implies 102.4% upside from current levels.
GLTO's current price is $21.58 with a consensus target of $43.67 (102.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $46 for GLTO, while the most conservative target is $40. The consensus of $43.67 represents the median expectation. These targets typically reflect 12-month expectations.
GLTO is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GLTO stock forecast based on 5 Wall Street analysts shows a consensus price target of $43.67, with estimates ranging from $40 (bear case) to $46 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on GLTO, with a "Buy" consensus rating and $43.67 price target (102.4% upside). 3 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GLTO analyst price targets range from $40 to $46, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $43.67 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.